9 out of 10 physicians say it is important to minimize patients’ out-of-pocket costs when prescribing3
NovoLog® makes analog insulin accessible1
NovoLog® exclusivea on Humana Part D and Commercial for 2017!
aExcept other rapid-acting insulins may be on the nonpreferred brand tier on plans with an open formulary.
Broad formulary coverage to help reach more lives2,b,c
bFormulary data are provided by Fingertip Formulary® and are current as of January 2017. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. ⓒ 2017 Fingertip Formulary. All rights reserved.
cManaged care plans only. Does not include Medicaid and Medicare Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs. Formulary status is subject to change. Multiple products within the same therapeutic class may be considered preferred and on the same tier.
More units. Same co-pay
One box of NovoLog® FlexPen® provides 50% more insulin than a vial for the same co-pay on most Commercial health care and Medicare Part D plans